Table 2.

Basic information of the included literature.

Number	Study	Year	Country/region	Age median	Study type	Number of patients	Prostate-specificantigen level
1	Ito et al. [13]	2011	Japan	70	Prospective	80	40 ng/mL
2	Yamada et al. [14]	2019	Japan	75	Retrospective	196	397.15 ng/mL
3	Merriel et al. [15]	2021	England	74.38	Retrospective	10 901	—
4	Prins et al. [16]	2012	USA	71.9	Prospective	119	80.8 (0.8–2113) ng/mL
5	Beer et al. [17]	2008	USA	69.5	Prospective	160	107 (4–6288) ng/mL
6	Hall et al. [18]	2013	USA	64	Retrospective	206	14.7 [0.48–166] ng/mL
7	Ilktac et al. [19]	2021	Turkey	66.85	Retrospective	149	—
8	Stikbakke et al. [20]	2019	Norway	71.7	Prospective	7356	14.3 μg/L
9	Stark et al. [21]	2009	USA	59.4	Prospective	22071	—
10	Xu et al. [22]	2015	China	65	Retrospective	135	80 ng/mL
11	Benli et al. [23]	2018	Turkey	67.6	Retrospective	231	6.87 ± 7.27 (PCa) and 0.91 ± 0.6 ng/dl (control)
12	Tulloch-Reid [10]	2017	Africa	65.4	Retrospective	481	—